ArticleFrontiers in medicine2026
Clinical spectrum and prevalence associations of chorioretinal damage in high myopia: a retrospective cross-sectional analysis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High myopia is a growing public-health challenge linked to irreversible chorioretinal damage and vision loss. Understanding its clinical spectrum and identifying predictors of early structural injury are essential for risk-stratified surveillance. Despite progress in imaging and diagnostic classification, population-level evidence describing lesion patterns and predictive factors in high-burden clinical settings remains limited. Methods: The cross-sectional retrospective study evaluated 1,420 patients (2,610 eyes) with high myopia examined between 2015 and 2024 at Lanzhou Aier Eye Hospital. Eligibility was based on refractive or biometric criteria and availability of multimodal imaging. Chorioretinal changes were graded using the ATN classification. Descriptive statistics summarized demographics and imaging findings. Prevalence of each lesion type was estimated with confidence intervals. Univariable comparisons and multivariable logistic regression with clustered variance identified independent predictors. Model calibration and discrimination were assessed, with prespecified sensitivity analyses based on axial length, age strata, and exclusion of treated choroidal neovascularization. Missing data were imputed using chained equations. Results: Chorioretinal damage was documented in 40.0% of eyes. Diffuse atrophy (16.1%), foveoschisis (11.9%), and patchy atrophy (8.2%) were the most frequent lesions. Older age, greater axial length, more negative spherical equivalent, and thinner choroid were independently associated with the presence of pathology. The final model demonstrated stable calibration and high discrimination across sensitivity analyses. Projected estimates indicated considerable population-level burden, particularly in individuals with axial length ≥32 mm. Conclusion: High-myopia eyes show substantial structural vulnerability, and key biometric parameters can support targeted early surveillance. The findings contribute new epidemiological evidence from a large clinical cohort and highlight practical risk-stratification markers suitable for public-health planning in regions facing rapid growth in myopia prevalence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.